Efficacy and Safety of Trastuzumab in the First-line Treatment of 66 Patients with HER2-positive Metastatic Breast Cancer
Author(s): HUANG Ping, LIU Yajuan, CHEN Zhanhong, ZHENG Yabing, SUN Yan, LOU Caijin, HUANG Jian, CAO Wenming, SHAO Xiying, WANG Xiaojia
Pages: 517-522
Year: 2017 Issue: 6
Journal: Journal of Oncology
Keyword: trastuzumab; breast neoplasms; metastasis; efficacy; safety;
Abstract: [Objective] To investigate the efficacy and safety of trastuzumab in the treatment of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer.[Methods] The clinical efficacy and side effects of trastuzumab plus chemotherapy in the first-line treatment of 66 patients with HER2-positive metastatic breast cancer were analyzed retrospectively.Cardiac function changes in left ventricular ejection fraction(LVEF) were monitored by color echocardiography.[Results] Three patients had complete remission (CR)(4.54％),52 patients had partial remission (PR)(78.79％),9 patients had disease stable (SD)(13.64％),and 2 patients had disease progression (PD)(3.03％).The objective response rate (ORR) was 83.33％(55/66).The median progression-free survival(mPFS) was 12.0 months.The median overall survival(OS)was 38.0 months.The 1-,2-,3-,5-,and 10-year survival rates were.98.5％,80.3％,57.6％,30.3％ and 11.4％.Univariate and multivariate analyses showed that the number of metastatic lesions was an independent prognostic factor of PFS (P＜0.05).The number of metastatic lesions and the cumulative use time of trastuzumab were independent prognostic factors of OS(P＜0.05).The main trastuzumab-related adverse reaction was degression of cardiac function,and the most severe was grade 3 LVEF decline,and the incidence was 1.5％(n=1).[Conclusion] Trastuzumab as the first-line treatment in patients with HER2-positive metastatic breast cancer is effective and safe.Early long-term use of trastuzumab in patients with small load metastases can lead to survival benefit.
Pages: 517-522
Year: 2017 Issue: 6
Journal: Journal of Oncology
Keyword: trastuzumab; breast neoplasms; metastasis; efficacy; safety;
Abstract: [Objective] To investigate the efficacy and safety of trastuzumab in the treatment of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer.[Methods] The clinical efficacy and side effects of trastuzumab plus chemotherapy in the first-line treatment of 66 patients with HER2-positive metastatic breast cancer were analyzed retrospectively.Cardiac function changes in left ventricular ejection fraction(LVEF) were monitored by color echocardiography.[Results] Three patients had complete remission (CR)(4.54％),52 patients had partial remission (PR)(78.79％),9 patients had disease stable (SD)(13.64％),and 2 patients had disease progression (PD)(3.03％).The objective response rate (ORR) was 83.33％(55/66).The median progression-free survival(mPFS) was 12.0 months.The median overall survival(OS)was 38.0 months.The 1-,2-,3-,5-,and 10-year survival rates were.98.5％,80.3％,57.6％,30.3％ and 11.4％.Univariate and multivariate analyses showed that the number of metastatic lesions was an independent prognostic factor of PFS (P＜0.05).The number of metastatic lesions and the cumulative use time of trastuzumab were independent prognostic factors of OS(P＜0.05).The main trastuzumab-related adverse reaction was degression of cardiac function,and the most severe was grade 3 LVEF decline,and the incidence was 1.5％(n=1).[Conclusion] Trastuzumab as the first-line treatment in patients with HER2-positive metastatic breast cancer is effective and safe.Early long-term use of trastuzumab in patients with small load metastases can lead to survival benefit.
Related Articles